Gilead Sciences, Inc. v. Merck & Co, Inc. et al. 5:13-cv-04057; Filed: 08/30/2013;
Closed: 06/06/2016; Latest Docket Entry: 12/06/2016; PACER. Thank you for ...
Aug 30, 2013 ... Patent case filed on August 30, 2013 in the California Northern District Court.
COLICCHIO v. MERCK & CO., INC. et al, No. 2:2008cv03593 - Document 103 (
D.N.J. 2012) case opinion from the District of New Jersey U.S. Federal District ...
Aug 11, 2016 ... Parties, docket activity and news coverage of federal case Gilead Sciences, Inc. v
. Merck & Co, Inc. et al, case number 5:13-cv-04057, from ...
Apr 27, 2010 ... Merck & Co., Inc. v. ... Joint Appendix Volume I · Brief for Respondent Richard
Reynolds, et al. Reply Brief for Petitioner Merck & Co. ... Brief for Dr. Harlan M.
Krumholz and Dr. Joseph S. Ross in Support of Respondents ...
Apr 27, 2010 ... Detroit Timber & Lumber Co., 200 U. S. 321, 337. SUPREME COURT OF THE
UNITED STATES. Syllabus. MERCK & CO., INC., ET AL. v.
Jan 20, 2007 ... Harlan M Krumholz, Harold H Hines Junior professor of medicine and ...
Rofecoxib (Vioxx) was introduced by Merck in 1999 as an effective, safer .....
Letter re: financial disclosure for Merck and Co, Inc sponsored protocol entitled: ...
Deborah Shapiro, et al. re: fw: for review [peer]: 2001-ms-2470 (full paper) .....
Nov 23, 2009 ... Merck & Co Inc] March9 2000 ... Bresalier RSSandler RSQuan H et al. ... COX-2
inhibitor rofecoxib vs ibuprofen in patients with osteoarthritis.
Merck, the maker of rofecoxib, promoted it as a safer alternative to traditional .... to
rofecoxib at the request of plaintiffs and against Merck and Co., Inc. While the
authors .... Our analysis builds upon the prior work of Jüni et al., published shortly
after ..... of the COX-2 inhibitor rofecoxib vs ibuprofen in patients with
Jun 20, 2016 ... They evaluated a bihormonal pump vs conventional insulin pump therapy in
adults .... Elkhatib F, Buckingham BA, Buse JB, Harlan DM, et al. ... Therapeutics,
Inc., GI Dynamics, Inc., Lexicon Pharmaceuticals, Inc., Merck & Co., ...